Results 81 to 90 of about 30,955 (215)
Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
Liesbeth Van Cleemput,1,2 Freya Peeters,1,2 Julie Jacob1,2 1Department of Ophthalmology, University Hospital Leuven, Leuven, Belgium; 2Research Group Ophthalmology, Department of Neurosciences, KU Leuven, Leuven, BelgiumCorrespondence: Liesbeth Van ...
Van Cleemput L, Peeters F, Jacob J
doaj
PurposeTo test the hypothesis that the performance in novel computer-based tasks of everyday visual function worsens with disease severity in people with non-neovascular age-related macular degeneration.MethodsParticipants with and without non ...
Bethany E Higgins +4 more
doaj +1 more source
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. [PDF]
The purpose of our study was to investigate the two-year outcome of Aflibercept treatment for neovascular age-related macular degeneration (nAMD), using the Observe-and-Plan regimen, an individually planned treatment regimen, based on the predictability ...
Ambresin, A. +4 more
core +1 more source
Visual Function Assessment in Geographic Atrophy: A Review
ABSTRACT Geographic atrophy (GA) causes significant vision impairment and reduction in vision‐related quality of life. Fundus autofluorescence (FAF) is the gold standard of structural assessment of GA but is a surrogate marker for vision loss, which can be assessed by tests of visual function and functional vision.
Ye Li, Lauren N. Ayton, Adrian T. Fung
wiley +1 more source
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited [PDF]
BACKGROUND: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of ...
Adam Turpcu +4 more
core +1 more source
Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies +8 more
wiley +1 more source
The results of aflibercept therapy as a first line treatment of age-related macular degeneration
Purpose: To report the results of aflibercept treatment in treatment-naive neovascular age-related macular degeneration (AMD) patients and suggest a suitable treatment algorithm for routine clinical practice.
Erkan Unsal, Mehmet Ozgur Cubuk
doaj +1 more source
An eye on long‐duration spaceflight: Controversies, countermeasures and challenges
Abstract Space flight‐associated neuroocular syndrome (SANS) is a consequence of long‐duration space flight and is detected in two‐thirds of astronauts. In‐flight, this can cause a change in the refraction of the eyes, requiring graded hypermetropic ‘superfocus adjustable’ glasses, optic nerve head oedema and choroidal folds.
Vincent Wing Sum Ng +1 more
wiley +1 more source
Abstract Purpose To examine the presence of secretory autophagy and epithelial–mesenchymal transition (EMT) in the macular retinal pigment epithelium (RPE) of human cadaver eyes with different forms of age‐related macular degeneration (AMD). Methods Human cadaver macula samples representing dry and wet AMD, as well as age‐matched controls, were ...
Iswariyaraja Sridevi Gurubaran +3 more
wiley +1 more source
Effects of Vitreomacular Adhesion on Age-Related Macular Degeneration
Herein, we review the association between vitreomacular adhesion (VMA) and neovascular age-related macular degeneration (AMD). Meta-analyses have shown that eyes with neovascular AMD are twice as likely to have VMA as normal eyes.
Eui Chun Kang, Hyoung Jun Koh
doaj +1 more source

